Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Genertec Universal Medical Group Co's Return-on-Tangible-Equity or its related term are showing as below:
HKSE:02666'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 11.68 Med: 14.12 Max: 16.79
Current: 11.82
During the past 12 years, Genertec Universal Medical Group Co's highest Return-on-Tangible-Equity was 16.79%. The lowest was 11.68%. And the median was 14.12%.
HKSE:02666's Return-on-Tangible-Equity is ranked better than 65.09% of 530
companies
in the Credit Services industry
Industry Median: 7.375
vs HKSE:02666: 11.82
Genertec Universal Medical Group Co (HKSE:02666) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Genertec Universal Medical Group Co Return-on-Tangible-Equity Related Terms
Genertec Universal Medical Group Co Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genertec Universal Medical Group Co Return-on-Tangible-Equity Chart
HKSE:02666 vs V, MA, AXP: Return-on-Tangible-Equity Comparison
For the Credit Services subindustry, Genertec Universal Medical Group Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genertec Universal Medical Group Co Return-on-Tangible-Equity vs Credit Services Industry
For the Credit Services industry and Financial Services sector, Genertec Universal Medical Group Co's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Genertec Universal Medical Group Co's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 9.96% mean?
Genertec Universal Medical Group Co (HKSE:02666) has a Return-on-Tangible-Equity of 9.96% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Genertec Universal Medical Group Co and its competitors. This is 29% below median its historical median of 14.12. Over the past decade, Genertec Universal Medical Group Co's Return-on-Tangible-Equity has ranged from 11.68 to 16.79. According to the industry distribution chart, Genertec Universal Medical Group Co ranks #185 out of 530 companies in the Credit Services industry, placing it in the top 34.9%.
Is Genertec Universal Medical Group Co's Return-on-Tangible-Equity too high?
Genertec Universal Medical Group Co's current Return-on-Tangible-Equity of 9.96% is 29% below median its 10-year median of 14.12. Over the past 10 years, this metric has ranged from a low of 11.68 to a high of 16.79. The Credit Services industry median Return-on-Tangible-Equity is 7.38. Genertec Universal Medical Group Co's value of 9.96% is 35.1% above this industry median. Based on the distribution chart, Genertec Universal Medical Group Co ranks #185 out of 530 companies in the Credit Services industry, which is above the industry midpoint. Overall, Genertec Universal Medical Group Co has a GF Score™ of 84/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Genertec Universal Medical Group Co's Return-on-Tangible-Equity compare to V and MA?
According to the Credit Services industry distribution chart, Genertec Universal Medical Group Co ranks #185 out of 530 companies for Return-on-Tangible-Equity. This puts Genertec Universal Medical Group Co in the upper half of its industry. The industry median Return-on-Tangible-Equity is 7.38. Genertec Universal Medical Group Co's value of 9.96% is 35.1% above this benchmark. Historically, Genertec Universal Medical Group Co's own Return-on-Tangible-Equity has ranged from 11.68 to 16.79 over the past decade. While the company's 10-year median is 14.12 vs. the industry median of 7.38, Genertec Universal Medical Group Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Credit Services company?
The median Return-on-Tangible-Equity among Credit Services companies is 7.38, based on 530 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genertec Universal Medical Group Co's current Return-on-Tangible-Equity of 9.96% is 35.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Genertec Universal Medical Group Co and its competitors. For the Credit Services industry, the median Return-on-Tangible-Equity is 7.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genertec Universal Medical Group Co's current Return-on-Tangible-Equity is 9.96%, which is 29% below median its own 10-year median of 14.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genertec Universal Medical Group Co stock overvalued right now?
Based on GuruFocus' analysis, Genertec Universal Medical Group Co (HKSE:02666) is currently considered Fairly Valued. The stock's GF Value™ is HK$4.51, compared to a current price of HK$4.67 — trading 3.5% above its estimated fair value. The current Return-on-Tangible-Equity is 9.96%, which is 29% below median its 10-year median of 14.12 and 35.1% above the Credit Services industry median of 7.38. Genertec Universal Medical Group Co's overall GF Score™ is 84/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Genertec Universal Medical Group Co (HKSE:02666), the current Return-on-Tangible-Equity is 9.96% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genertec Universal Medical Group Co (HKSE:02666) Overvalued in 2026?
Based on GuruFocus' analysis, Genertec Universal Medical Group Co stock appears to be overvalued.
The current stock price of HK$4.67 is trading 3.5% above its estimated GF Value™ of HK$4.51.
GuruFocus considers Genertec Universal Medical Group Co to be Fairly Valued.
Key valuation signals for HKSE:02666:
Return-on-Tangible-Equity: 9.96% (29% below median its 10-year median of 14.12)
GF Value™: HK$4.51 vs. price of HK$4.67 (3.5% above fair value)
Industry Position: 35.1% above the Credit Services median (#185 of 530)
No single metric tells the full story. See the HKSE:02666 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genertec Universal Medical Group Co Ltd is principally engaged in providing financing to its customers under finance lease arrangements, the provision of advisory services, the sale of medical equipment as well as leases under operating lease arrangements, and the provision of other services. The group has two business segments namely The finance business comprises direct finance leasing, sale-and-leaseback, factoring, operating leases, and advisory services; and Healthcare business comprises includes hospital group business, healthcare technology business and specialty business. Geographically, it derives a majority of its revenue from Mainland China.
84GF Score
Get the complete analysis for HKSE:02666
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02666 has been successfully added to your 
